Our study suggests that PUM1 has better diagnostic performance potential than RNase P or a combination of both markers for the discrimination of healthy women (control group) and early‐stage BC patients (AUC = 0.999, Figure 4). This evidence concerns the gene PUM1 and breast cancer.